Lectin Protein as a Promising Component to Functionalize Micelles, Liposomes and Lipid NPs against Coronavirus.
Mehran AlaviKofi Asare-AddoAli NokhodchiPublished in: Biomedicines (2020)
The outbreak of a novel strain coronavirus as the causative agent of COVID-19 pneumonia, first identified in Wuhan, China in December 2019, has resulted in considerable focus on virulence abilities of coronavirus. Lectins are natural proteins with the ability to bind specific carbohydrates related to various microorganisms, including viruses, bacteria, fungi and parasites. Lectins have the ability to agglutinate and neutralize these pathogeneses. The delivery of the encapsulated antiviral agents or vaccines across the cell membrane can be possible by functionalized micellar and liposomal formulations. In this mini-review, recent advances and challenges related to important lectins with inhibition activities against coronaviruses are presented to obtain a novel viewpoint of microformulations or nanoformulations by micellar and liposomal cell-binding carriers.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- coronavirus disease
- drug delivery
- escherichia coli
- single cell
- drug release
- pseudomonas aeruginosa
- staphylococcus aureus
- cell therapy
- binding protein
- quantum dots
- cancer therapy
- stem cells
- amino acid
- biofilm formation
- intensive care unit
- mesenchymal stem cells
- mechanical ventilation
- dna binding
- low density lipoprotein
- oxide nanoparticles